Biodesix, Inc. (BDSX)

NASDAQ: BDSX · IEX Real-Time Price · USD
2.40
-0.02 (-0.83%)
At close: Jan 31, 2023, 4:00 PM
2.48
+0.08 (3.33%)
After-hours: Jan 31, 2023, 7:44 PM EST

Company Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States.

The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test.

In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection.

Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics.

The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Biodesix, Inc.
Biodesix logo
Country United States
IPO Date Oct 28, 2020
Industry Diagnostics & Research
Sector Healthcare
Employees 218
CEO Mr. Scott Hutton

Contact Details

Address:
2970 Wilderness Place, Suite 100
Boulder, Colorado 80301
United States
Phone 303-417-0500
Website biodesix.com

Stock Details

Ticker Symbol BDSX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001439725
CUSIP Number 09075X108
ISIN Number US09075X1081
Employer ID 20-3986492
SIC Code 8071

Key Executives

Name Position
Scott Hutton President, Chief Executive Officer and Director
Robin Harper Cowie Chief Financial Officer, Secretary and Treasurer
Ryan H. Siurek Chief Accounting Officer
Dr. Heinrich Röder Founder and Chief Technology Officer
Dr. Robert W. Georgantas III, Ph.D. Chief Scientific Officer
Jeffrey A. Bojar Vice President of Legal and Regulatory Affairs
Matt Stauffer Vice President of Sales
Dr. Paul J. Beresford Chief Business Officer
Dr. Gary Anthony Pestano Ph.D. Chief Development Officer
Bobbi Coffin Chief Growth Officer

Latest SEC Filings

Date Type Title
Jan 13, 2023 SC 13D General statement of acquisition of beneficial ownership
Dec 16, 2022 8-K Current Report
Dec 1, 2022 SC 13D General statement of acquisition of beneficial ownership
Nov 30, 2022 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 23, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 23, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 23, 2022 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 21, 2022 8-K Current Report
Nov 18, 2022 424B5 Filing
Nov 16, 2022 424B5 Filing